Cytokinetics (CYTK) is back in focus after its third quarter update, with revenue of US$47.56 million, a narrower loss, and fresh late stage data for heart drug aficamten adding to the MYQORZO story. The third quarter update has arrived after a choppy stretch for Cytokinetics, with the share price falling 17.14% over the past 90 days but still showing a 3.03% year to date share price gain and a 5.47% total shareholder return over twelve months. At the current US$63.60 share price, that mix of...
Cytokinetics (CYTK) delivered earnings and revenue surprises of +8.67% and +10.57%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
On Thursday, Cytokinetics (NASDAQ:CYTK) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial
Multi-center Prospective Study to Track Real-World Safety, Clinical Effectiveness, and Healthcare Resource Impact of MYQORZO in Routine Clinical Practice SOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the start of ASPEN-HCM (Aficamten Study of Patient Experience and Novel Outcomes in Symptomatic Obstructive HCM), a prospective, multicenter, observational real-world study evaluating MYQORZO® (aficamten) in adult patients w
This is the newest page. Registered accounts read further back.